Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Xilio Development Inc(XLO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for XLO
10/01/2026: XLO (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Xilio Development Inc is a clinical-stage biotechnology company focused on engineering tumor-selective immunotherapies. Its main strength lies in its proprietary GeoX platform, which aims to reduce the toxicity associated with traditional oncology treatments. The primary investment opportunity is the potential for its clinical-stage assets to achieve proof-of-concept and lead to high-value pharmaceutical partnerships. However, the company faces significant risks, including the inherent uncertainty of clinical trials, heavy reliance on external funding, and intense competition from larger, well-capitalized firms. This stock may suit investors with a high risk tolerance who are interested in the long-term potential of transformative immuno-oncology developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Xilio is a high-risk, high-reward play suitable only for investors comfortable with clinical trial volatility. |
| Momentum investor | Weak fit | Momentum is generally tied to positive clinical data catalysts rather than long-term technical trends. |
| Value investor | Weak fit | As a pre-revenue company, Xilio lacks the earnings base required for traditional value investing. |
| Dividend investor | Weak fit | The company does not pay dividends and reinvests all capital into research. |
| Low-risk investor | Weak fit | The extreme volatility of pre-commercial biotech makes this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks fluctuate wildly based on news of trial results or funding updates. |
| Valuation risk | High | Valuations are speculative and depend heavily on future, uncertain clinical outcomes. |
| Competition risk (Immunotherapy) | High | Large pharmaceutical companies are better positioned to dominate the immuno-oncology market. |
| Business quality | Medium | The company relies on its proprietary platform, which has yet to be commercially validated. |
| Dividend income | Low / none | Investors should not expect any income from this security. |
| Execution risk | High | Success depends entirely on the ability to navigate complex clinical and regulatory hurdles. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -55.07% | Avg. Invested days 16 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/01/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 59.55M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 9.5K shares | Beta -0.12 | 52 Weeks Range 6.47 - 12.59 | Updated Date 10/01/2026 |
52 Weeks Range 6.47 - 12.59 | Updated Date 10/01/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.32 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Research & Development | Clinical development of tumor-selective antibodies and cytokines. | The company currently spends money rather than making it, with future revenue dependent on successful drug development. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -70.91M | Price to Sales(TTM) 0.93 |
Enterprise Value -70.91M | Price to Sales(TTM) 0.93 | ||
Enterprise Value to Revenue 10.21 | Enterprise Value to EBITDA -0.11 | Shares Outstanding 6.58M | Shares Floating 3.40M |
Shares Outstanding 6.58M | Shares Floating 3.40M | ||
Percent Insiders 25.98 | Percent Institutions 50.16 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Xilio Development Inc
Exchange NASDAQ | Headquarters Waltham, MA, United States | ||
IPO Launch date 2021-10-22 | President, CEO & Director Dr. Rene Russo BCPS, Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 76 | Website https://xiliotx.com |
Full time employees 76 | Website https://xiliotx.com | ||
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.